Astrazeneca's breast cancer drug fails late-stage trial
Astrazeneca's breast cancer drug fails late-stage trial Sept 11 (Reuters) - AstraZeneca AZN.L said on Friday its breast cancer drug failed to meet the main goal of improving progression-free survival during a late-stage trial.
(Reporting by Christy Santhosh in Bengaluru; Editing by Tasim Zahid)
Recent news on Pfizer
See all newsFactbox: Pharma sector doubles down on AI to slash costs, timelines
Focus: Beauty giants target 'Ozempic face' as boom in obesity drugs opens new market
Eli Lilly hits record high as healthcare stocks rally
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Factbox: Major drugmakers turn to China for licensing deals